stockrowCabot Corporation
CBT Basic Materials Specialty Chemicals
Cabot Corporation’s revenue for fiscal 2025 (year ended September 2025) was $3.7 billion, down 7.04% from fiscal 2024.
- Revenue
- +12.2%
- EPS
- +79.4%
- Free cash flow
- −51.7%
- Total debt
- +10.8%
Quarter to September 2026, against a year earlier
Follow CBT
Alert me
Cabot Corporation (CBT) EPS (diluted)
Cabot Corporation's EPS (diluted) for fiscal 2025 was $6.02, down 10.4% from $6.72 in fiscal 2024. Over the twelve months to 30 September 2026 it was $4.17. Over the past ten years it has ranged from −$5.23 (fiscal 2015) to $7.73 (fiscal 2023); the current reading is higher than 82% of that period. Cabot Corporation ranks 13th of 56 Specialty Chemicals companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $6.02 | (10.42%) |
| FY2024 | $6.72 | (13.07%) |
| FY2023 | $7.73 | 113.54% |
| FY2022 | $3.62 | (16.59%) |
| FY2021 | $4.34 | — |
| FY2020 | −$4.21 | — |
| FY2019 | $2.63 | — |
| FY2018 | −$1.85 | — |
| FY2017 | $3.81 | 61.44% |
| FY2016 | $2.36 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $1.41 | 1,072.17% |
| Jun 2026 | $0.12 | (90.55%) |
| Mar 2026 | $1.27 | (7.30%) |
| Dec 2025 | $1.37 | 73.42% |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| WDFC WD-40 Company compare | $6.08 |
| CBT Cabot Corporation | $4.17 |
| HWKN Hawkins, Inc. compare | $4.12 |
| SXT Sensient Technologies Corporation compare | $3.97 |
| FUL H. B. Fuller Company compare | $3.59 |
| AVNT Avient Corporation compare | $1.96 |
| PRM Perimeter Solutions, SA compare | $0.13 |
| ASH Ashland Inc. compare | $0.08 |
| CLMT Calumet, Inc. compare | −$1.55 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on CBT
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement